Galectin Therapeutics, a leading developer of therapeutics that specifically target galectin proteins in order to treat fibrosis and types of cancer, announced today that Jack W. Callicutt has been recruited to the position of Chief Financial Officer; effective as of July 1, 2013.
Callicutt will oversee Galectin’s financial activities, of which include interaction with capital markets, financial reporting, accounting, risk management, public company governance, as well as public and investor relations. As an active member of the senior management team, Callicutt will play a key position in shaping overall corporate strategy and advising on advance key product assets in the clinic. He will also help insure that financial resources are realized in order to achieve its vision for its pipeline of clinical development assets, a necessity in order to create shareholder value.
“Jack’s demonstrated leadership and deal-making capabilities coupled with his financial management experience and industry knowledge makes him an ideal fit with the needs of the company and further consolidates our leadership group in the Atlanta office. I am looking forward to working closely with Jack and am excited to add an individual of Jack’s caliber to our management team,” stated Dr. Peter G. Traber, Chief Executive Officer and Chief Medical Officer of Galectin Therapeutics Inc. “I also wish to sincerely thank Mr. Thomas McGauley for his years of service to the company, including the last 14 months as acting CFO, and for agreeing to work closely with Jack to assure an orderly transition.”
With over 22 years of public and private company experience, Callicutt holds more than a decade of audit, tax, and SEC registrant experience with a major accounting firm. Most recently he held the position of CFO for REACH Health, Inc., a telemedicine firm, where he successfully implemented a $4 MM private placement. He also previously held positions that include the title of CFO of Vystar Corporation, where he oversaw all areas of financial reporting, accounting, treasury, risk management and administration, as well as secured over $4.5 MM in financing. Furthermore Callicutt acted as CFO for private companies, including IVOX, Tikvah Therapeutics, and Coratus Genetics, a publicly traded biopharmaceutical company. Noting his broad background of experiences spanning a variety of technology intensive industries followed by over a decade-long of holding senior level positions at Deloitte, Callicutt will be a great contribution to the advancement of Galectin.
Callicutt graduated cum laude with a BBA degree in Accounting and Computer science from Delta State University and is a Certified Public Account. Additionally, Callicutt is an active member in community affairs such as the Atlanta Community Food Bank and Habitat for Humanity. He currently resides with his family in Alpharetta, Georgia.
To learn more, visit www.galectintherapeutics.com
Let us hear your thoughts below:
